Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma.

• Status: Completed
• Trial end date: 2003-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This drug is being developed to treat a type of brain cancer, glioma. This study was designed to determine a safe and well tolerated dose. Patients must have had prior treatment for their glioma and be eligible for removal of their recurring tumor.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: TransMolecular

Criteria

• Patient must have given informed consent

• Patient must have histologically confirmed supratentorial malignant glioma

• Patients must have recovered from toxicity of prior therapy

• Patients must be eligble for resection of the recurrent tumor